TG Therapeutics’ (TGTX) Buy Rating Reiterated at HC Wainwright

Share on StockTwits

TG Therapeutics (NASDAQ:TGTX)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued on Tuesday, AnalystRatings.com reports. They currently have a $20.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 164.55% from the stock’s previous close.

Several other research analysts also recently commented on the company. BidaskClub upgraded TG Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, November 7th. Zacks Investment Research upgraded TG Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 price objective on the stock in a report on Saturday, November 2nd. Finally, ValuEngine downgraded TG Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, October 21st. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $12.55.

Shares of TGTX stock traded down $0.23 on Tuesday, reaching $7.56. 54,056 shares of the company’s stock were exchanged, compared to its average volume of 1,274,115. TG Therapeutics has a 52 week low of $3.32 and a 52 week high of $9.38. The company has a debt-to-equity ratio of 2.77, a current ratio of 1.69 and a quick ratio of 1.69. The company’s fifty day simple moving average is $6.02 and its 200 day simple moving average is $6.93.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Friday, August 9th. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.01. The company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative return on equity of 496.99% and a negative net margin of 99,488.13%. As a group, sell-side analysts predict that TG Therapeutics will post -1.52 earnings per share for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC increased its holdings in TG Therapeutics by 5.0% during the 2nd quarter. SG Americas Securities LLC now owns 30,858 shares of the biopharmaceutical company’s stock worth $267,000 after purchasing an additional 1,481 shares during the period. Rhumbline Advisers increased its holdings in TG Therapeutics by 2.1% during the 3rd quarter. Rhumbline Advisers now owns 95,679 shares of the biopharmaceutical company’s stock worth $537,000 after purchasing an additional 1,976 shares during the period. Aperio Group LLC purchased a new position in TG Therapeutics during the 2nd quarter worth $32,000. Parametric Portfolio Associates LLC increased its holdings in TG Therapeutics by 45.4% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 21,152 shares of the biopharmaceutical company’s stock worth $183,000 after purchasing an additional 6,609 shares during the period. Finally, Bank of Montreal Can increased its holdings in TG Therapeutics by 1,119.0% during the 2nd quarter. Bank of Montreal Can now owns 8,143 shares of the biopharmaceutical company’s stock worth $70,000 after purchasing an additional 7,475 shares during the period. Institutional investors own 52.30% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Further Reading: Insider Trading – What You Need to Know

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Intesa Sanpaolo SpA  Given Average Recommendation of “Hold” by Analysts
Intesa Sanpaolo SpA Given Average Recommendation of “Hold” by Analysts
$14.18 Million in Sales Expected for Quanterix Corp  This Quarter
$14.18 Million in Sales Expected for Quanterix Corp This Quarter
Sandy Spring Bancorp Inc.  Sees Significant Increase in Short Interest
Sandy Spring Bancorp Inc. Sees Significant Increase in Short Interest
EtherInc Trading Down 16.8% This Week
EtherInc Trading Down 16.8% This Week
Wagerr  Hits Market Cap of $5.89 Million
Wagerr Hits Market Cap of $5.89 Million
Fatcoin  Tops 1-Day Volume of $1.34 Million
Fatcoin Tops 1-Day Volume of $1.34 Million


© 2006-2019 Ticker Report